Close Menu

Breaking News

TC agreed with a judge who said that 10x's older GEM microfluidic chips infringed Bio-Rad patents, but that the firm's new Next GEM chips did not.

The first phase of the study to evaluate Telo Genomics' telomere analytics as a prognostic solution for multiple myeloma is expected to launch in Q1 2020.

The exclusive distribution deal expands the Finnish bioinformatics software company's footprint in the Middle East, Africa, and Asia.

Palmetto has expanded the local coverage determination for the Guardant360 liquid biopsy assay to be used with the majority of advanced solid tumors.

The company has raised $30 million to date to fund development and commercialization of its molecular diagnostic test to predict response to anti-TNF therapies.

St. Jude Children's Research Hospital researchers evaluated a microbial cell-free DNA sequencing test from infectious disease diagnostics firm Karius.

Effective Feb. 3, 2020, the donor-derived cell-free DNA test will be covered for all kidney transplant recipients, including those with multiple kidney transplants.

Investigators analyzed the expression of protein-coding genes in 18 blood immune cell populations, comparing the expression profiles with those in other cell and tissue types.

The firm did an initial close of its Series A financing round and will pursue additional investments during Q1 2020 when the round is anticipated to close.

Promega said it plans to use the technology to create new research products for investigating endogenous biology.

The financing was led by HealthQuest Capital, with participation from 5AM Ventures and RareCyte founder Ron Seubert, and follows a $30 million round in 2017.

Computational hardware maker Nvidia has purchased Parabricks, which has applied GPU technology to bring whole-genome sequencing processing time under an hour.

As part of the distribution agreement, Biolidics will distribute the IncellDx bioINK kit with Biolidics' ClearCell FX1 system.

The researchers are aiming to provide new insights as to which cancer patients will respond best to immunotherapy based on their genetic backgrounds.

IQvia, the lead investor in this round, will work with BC Platforms to integrate genomic and clinical data in a secure environment to support biomedical research.

Individuals with high genetic susceptibility to heart disease but good sleep habits appeared less likely to develop disease than those with poor sleep patterns.

The Federal Trade Commission has authorized staff to use legal action to block the deal pending an administrative trial, set for August 2020.

The firm plans to raise as much as $250 million, according to the document filed with the US Securities and Exchange Commission.

The company will use the funding to market its GoodCell Diagnostics service, which combines genetic testing and personally controlled biobanking.

With metagenomic sequencing on birch pitch, investigators sequenced a 5,700-year-old individual from Sweden, along with sequences from her meal and her oral microbes.

The company said that it plans to use the funds to develop and commercialize its Proteograph proteomics platform for research and clinical applications.

Perceptive Advisors led the round, joined by new and existing investors. ArcherDx will use the proceeds to launch a companion diagnostic and expand globally.

The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.

The firm will use the new funds to accelerate development of products, expand partnerships, and support commercialization of its two multiplex panels.

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.